[Memphis, TN] – Hera Health Solutions, a pharmaceutical device company and innovator in long-acting drug delivery technology, is proud to announce a significant milestone in its growth. The company has entered into an exclusive licensing agreement with Geovista, a leading animal health pharmaceutical company based in South Korea. This deal represents the expansion of Hera’s proprietary drug delivery platform technology into the rapidly growing Asian therapeutics market.
The deal grants Geovista rights to utilize Hera's cutting-edge platform for a single veterinary drug candidate across Asia. With the deal projected to generate a high-value eight to nine-figure return for Hera, the partnership highlights the versatility and global scalability of Hera's breakthrough technology, which has already demonstrated its success across multiple other therapeutic areas. With this agreement, Hera is poised to further expand its drug delivery platform to other drug candidates, continuing to prove its flexibility in adapting to both human and veterinary therapeutics. The bioerodible technology allows for controlled, long-term release of active pharmaceutical ingredients, providing a significant competitive edge in the market. This expansion into animal health opens new avenues for applying the platform to enhance drug efficacy, reduce dosing frequency, and meet the growing demand for sustained-release therapies in both emerging and established markets.
"This partnership with Geovista is a key step in our strategic plan to scale the platform technology globally," said Idicula Mathew, CEO of Hera Health Solutions. "We anticipate many more opportunities across other therapeutic areas and markets. This deal underscores the strong market demand for Hera’s platform”. The platform’s ability to increase drug effectiveness while reducing potential side effects by controlling steady dosing makes it an attractive solution for both human and veterinary pharmaceuticals.
Geovista's extensive reach in the Asian veterinary market, combined with Hera’s innovative drug delivery system, will address the region's growing need for efficient, long-term therapeutic solutions. The collaboration is expected to pave the way for more impactful veterinary treatments and set the stage for future licensing agreements in other regions and drug applications.
Dr. Gook Jun Ahn, CEO of Geovista, and a renowned veterinarian, expressed his enthusiasm for the partnership: "At Geovista, we are constantly looking for innovative solutions to improve outcomes for animal health, and Hera Health Solutions’ platform offers a unique advantage with its long-acting, bioerodible technology. This collaboration will allow us to deliver more effective treatments that reduce the need for frequent dosing and set new standards for sustained-release therapies for veterinary medicine across Asia."
Hera Health Solutions continues to build a robust portfolio of global partnerships, leveraging its platform technology across a wide range of sectors, including human health, veterinary medicine, and sustained release drug delivery. This new licensing agreement marks a significant step toward the company's long-term goal of revolutionizing drug delivery solutions worldwide.
###
About Hera Health Solutions: Hera Health Solutions is a pharmaceutical device company specializing in research, development, and commercialization of long-acting treatments through proprietary bioerodible drug delivery implants. Committed to innovation, Hera Health Solutions aims to revolutionize healthcare by creating impactful, patient-centric solutions that improve lives globally.
About Geovista: Geovista is a leading animal health pharmaceutical company based in South Korea, specializing in the development and commercialization of innovative animal health solutions. With a strong focus on advancing veterinary medicine, Geovista is dedicated to improving the well-being of animals by delivering cutting-edge therapies that address the evolving needs of the global veterinary market. The company leverages deep expertise in pharmaceuticals and a commitment to research and development, ensuring high-quality treatments for a wide range of animal health conditions. Geovista’s mission is to set new standards in veterinary care, driving innovation in therapeutic solutions to enhance the quality of life for animals across Asia and beyond.
Images and Usage Rights
All images included in this press release are owned by Hera Health Solutions Inc.
Commentaires